Silo Pharma’s SPC-15 Shows Promising Preclinical Results For Treating Major Depressive Disorder

Silo Pharma, Inc., a biopharmaceutical company developing innovative therapies and drug delivery methods for conventional and psychedelic treatments, has announced positive results of preclinical trials for SPC-15. This novel formulation targets both the serotonin 5-HT4 receptor (5-HT4R) and the NMDA receptor (NMDAR) and has shown promise in treating major depressive disorder (MDD) and other severe stress-related conditions.

The preclinical study explored the efficacy of combining SPC-15, a 5-HT4R agonist, with an NMDAR antagonist to address stress-induced behaviours. Findings from animal models suggest this dual-targeted approach could provide enhanced therapeutic effects compared to using either agent alone, positioning it as a potential treatment for challenging psychiatric conditions.

The top findings are as follows:

• Enhanced outcomes through dual targeting, which targets both 5-HT4R and NMDAR, produced significant improvements in stress-related behaviours, surpassing the efficacy of single-agent treatments. 

  
  

• An additive advantage of combination therapy is that dual therapy has resulted in a significant reduction of stress-induced behaviours, thus promising to be an effective treatment for drug-resistant depression.

  
  

Eric Weisblum, CEO of Silo Pharma, said in a statement, “We are encouraged by these results, which point to what we believe is a promising new approach for managing severe stress-related psychiatric disorders. In our opinion, our dual-action strategy with SPC-15 demonstrates the potential to provide an effective treatment option for patients experiencing severe and relapsed stress-related disorders.”

He also commented, “We believe these findings further support our continuing development of SPC-15 as an intranasal prophylactic treatment for PTSD. We are advancing this program with a goal of an IND submission for first-in-human trials.”